Latest news with #ProfoundMedical
Globe and Mail
2 days ago
- Business
- Globe and Mail
Profound Medical Posts Wider Loss in Q2
Key Points Revenue (GAAP) declined slightly year over year to $2.2 million in Q2 2025, missing GAAP revenue estimates by 32.3% on delayed capital sales. Operating expenses (GAAP) climbed approximately 65.8%, pushing net loss (GAAP) to $15.7 million, Net loss for the quarter ended June 30, 2025, increased approximately 127.5% year over year. Management reiterated its annual revenue growth target of 70–75% year-over-year in 2025; with the outlook relying on a sharp second-half rebound in 2025. These 10 stocks could mint the next wave of millionaires › Profound Medical (NASDAQ:PROF), a medical technology company specializing in minimally invasive prostate therapies, reported its GAAP financial results for Q2 2025 on August 14, 2025. The company reported no GAAP revenue growth compared to the prior-year period, with total GAAP revenue of $2.2 million, well below analysts' expectations of $3.25 million. The company's net loss widened to $15.7 million, or $0.52 per share (GAAP). The quarter saw higher operating costs and a delay in capital equipment deals, contributing to weaker-than-expected performance. Despite these headwinds, management reaffirmed its full-year 2025 guidance for strong revenue growth in the approximate range of 70% to 75% year-over-year, but the results highlight ongoing execution risks. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Snapshot and Strategic Priorities Profound Medical develops technologies for image-guided, minimally invasive treatments for prostate diseases. Its flagship TULSA-PRO system enables physicians to ablate (destroy) prostate tissue using real-time magnetic resonance imaging (MRI) and high-intensity ultrasound. The Sonalleve system, another platform, is used for the treatment of uterine fibroids and other conditions with focused ultrasound. The company's near-term focus is to expand adoption of its TULSA-PRO system in the U.S. and abroad, leveraging recent regulatory wins and reimbursement changes. Key to success are continued clinical validation, conversion of sales pipeline opportunities into system placements, and growing a reliable stream of recurring revenue from consumables, leases, and services tied to each installed system. Profound Medical's ability to manage costs and extend its cash runway until recurring revenue can support operations is also critical, given its current reliance on external funding. Quarter in Review: Operations and Financials The company experienced a stalled top line, reporting $2.2 million in GAAP revenue for Q2 2025—virtually unchanged from the prior year and substantially below consensus estimates. This GAAP revenue miss was attributed to short-term delays in closing several capital sales for TULSA-PRO systems. According to management, had these deals been completed during the quarter, revenue would have topped $3 million. Recurring revenue from procedures, disposables, and service grew by 6.9%, rising from $1.46 million in Q2 2024 to $1.56 million in Q2 2025 (GAAP), and accounted for most of the total revenue. Sales of capital equipment dropped slightly, reflecting the postponed deals. Meanwhile, procedure volumes continued to rise at existing customer sites, with 'same-store' utilization up 10% from Q1 2025. The sales pipeline for new TULSA-PRO system placements increased, with 80 systems in advanced negotiation stages as of quarter end. This suggests strong demand, but actual conversion of this pipeline into revenue remains a known risk. The company's product portfolio saw notable milestones: The TULSA-AI Volume Reduction Module—an artificial intelligence-based add-on for treating benign prostatic hyperplasia (BPH)—completed its first commercial procedure and soft-launched at five sites, with a full release planned for the fourth quarter of 2025. Profound Medical also continued to develop 'TULSA+,' a program to bundle TULSA-PRO with MRI scanners from Siemens, with commercial sales expected to launch before the end of 2025. The TULSA-PRO system received important clinical validation during the period. Initial data from the CAPTAIN randomized trial showed the device provides a statistically significant improvement in post-operative experience compared to traditional robotic prostatectomy—patients experienced no blood loss, faster recovery, and less pain. This data gives the product a competitive edge and is being rolled out at key clinical meetings to boost awareness and drive adoption. Gross margin (GAAP) improved to 73%, up from 64% a year earlier in Q2 2025, reflecting more efficient manufacturing. However, the gain could not offset a jump in operating costs, which rose approximately 65.6% year-over-year to $15.4 million (GAAP). Research and development (R&D) spending rose to $6.1 million (GAAP). Selling, general, and administrative (SG&A) costs (GAAP) climbed to $9.3 million as Profound Medical increased headcount and built up commercial infrastructure to support market expansion and the CAPTAIN trial. The net loss (GAAP) widened to $15.7 million, up from $6.9 million in Q2 2024. Higher expenses with no corresponding revenue growth drove this result. Profound Medical ended Q2 2025 with $35.2 million in cash (GAAP), down from $54.9 million at December 31, 2024 (GAAP). Inventory levels also increased to $8.35 million (GAAP) as of quarter end, but the results highlight ongoing execution risks. Looking Forward For the remainder of FY2025, management maintained its guidance for total annual revenue growth of 70–75%, despite the weak first-half result. Achieving this will depend on a sharp ramp-up in capital systems sales and recurring revenue in the second half of 2025. This reflects management's expectation for a stronger pipeline conversion as new reimbursement codes, clinical data, and product launches come to fruition. The company stated that a 'back-end loaded' revenue profile is anticipated for 2025, consistent with the shift toward upfront capital equipment sales. Meeting these ambitious targets will require improved execution and more predictable closing of sales, as well as continued clinical advocacy of the TULSA-PRO platform. Investors should monitor: the rate at which pipeline deals materialize into revenue; expense growth relative to sales; and ongoing improvements in the balance of recurring versus one-time capital sales. PROF does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Sky News AU
14-06-2025
- Health
- Sky News AU
Medical experts unveil major clues to the type of "incurable" cancer King Charles could have been diagnosed with
Since Buckingham Palace confirmed King Charles had cancer in 2024, medical professionals around the globe have tried to determine exactly which type of disease he has. The palace said "diagnostic tests" found Charles' cancer during a "corrective" hospital procedure for a benign prostate enlargement, known as Benign Prostatic Hyperplasia (BPH), in a statement last February. BPH is characterised by an overgrowth of prostate tissue that pushes against the urethra and the bladder, restricting the flow of urine. Buckingham Palace has not disclosed what type of cancer the King has or what stage the disease is at while he continues to undergo treatment. However, it's been confirmed he does not have prostate cancer despite the initial hospital procedure being for an enlarged prostate. While the corrective procedure the King had is unknown, the most common one for BPH is Transurethral Resection of the Prostate (TURP). According to the Mayo Clinic, TURP involves a surgeon trimming away extra prostate tissue that is blocking the flow of urine. A transurethral ultrasound ablation (TULSA) is another treatment option for BPH. This innovative procedure is performed under MRI guidance, using targeted ultrasound waves to heat and destroy prostate tissue. Since Both TURP and TULSA involve removing prostate tissues, Profound Medical, which develops the TULSA device, suggests Charles could have bladder or kidney cancer after doctors examined his removed tissue. "The nature of King Charles's diagnosis is not uncommon and is referred to as an incidental diagnosis," Profound Medical said on its website. "This can occur when treatment for conditions like BPH leads to the unexpected discovery of other illnesses. "During procedures intended to relieve BPH symptoms, physicians might take the opportunity to examine removed tissue or conduct imaging tests that can reveal other conditions like bladder or kidney cancer or even unrelated cancers identified through routine imaging." According to the Cleveland Clinic, examining tissue from the prostate can also detect urethral cancer. The medical centre states people older than 60 who are males are more likely to get this cancer type. Moreover, data by Cancer Research UK suggests King Charles could have lung cancer or bowel cancer. The data states the most common cancers in UK males after prostate cancer (28 percent) are lung cancer (13 per cent) and bowel cancer (12 per cent) from 2017 through 2019. It also states head and neck, bladder, oesophageal cancers, and leukaemia are among the UK's ten most common cancers in males. The Cancer Council encourages men over the age of 50 to get tested for bowel cancer every two years. The palace continues to say the monarch is doing well, but veteran royal insider Camilla Tonminey said Charles' diagnosis is ultimately incurable. 'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' Ms Tonminey recently told The Telegraph. She said 'tentative' planning for Charles' 80th birthday celebrations in 2028 is going ahead with the expectation the King's cancer will continue to be managed. For the second consecutive year, Charles will not ride by horseback and will instead opt to go by carriage at Trooping the Colour on Saturday, according to The Times. The carriage was deemed a safer and more comfortable option at the King's official birthday parade last year after the King's procedure.
Yahoo
10-05-2025
- Business
- Yahoo
Profound Medical First Quarter 2025 Earnings: Misses Expectations
Revenue: US$2.62m (up 37% from 1Q 2024). Net loss: US$10.7m (loss widened by 73% from 1Q 2024). US$0.36 loss per share (further deteriorated from US$0.26 loss in 1Q 2024). Our free stock report includes 1 warning sign investors should be aware of before investing in Profound Medical. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 24%. Looking ahead, revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in North America. Performance of the market in Canada. The company's shares are down 13% from a week ago. We don't want to rain on the parade too much, but we did also find 1 warning sign for Profound Medical that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Associated Press
26-02-2025
- Business
- Associated Press
Profound Medical Standardizes on AcuityMD Intelligence Platform for MedTech as Foundation for Growing Organization
AcuityMD, the intelligence platform for the medical technology (MedTech) industry, has been selected by Profound Medical, a medical device company developing customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue – specifically for prostate diseases. Profound Medical is standardizing its organization on AcuityMD's complete suite of commercial intelligence solutions to bring its breakthrough TULSA-PRO® technology to more healthcare providers nationwide. Nearly 60% of men diagnosed with low-risk prostate cancer are managed with active surveillance – a 'wait-and-see' approach – because traditional treatments often cause severe, permanent side effects such as incontinence and erectile dysfunction. Profound Medical provides patients with a better alternative for whole or partial gland ablation, whether for low-risk, intermediate-risk, or more severe disease states. Indicated for transurethral ultrasound ablation (TULSA) of prostate tissue, TULSA-PRO is the first incision-free, radiation-free treatment for prostate disease. The procedure, which is now reimbursed by Medicare with a Category 1 CPT code, can also be conveniently performed in various outpatient settings – hospitals, ambulatory surgery centers, and office-based laboratories (OBLs). AcuityMD provided Profound Medical a smart, efficient way to accelerate the delivery of TULSA-PRO to healthcare providers. Profound Medical had been using a general customer relationship management (CRM) system with spotty market data. As a fast-growing company, they needed a powerhouse system with integrated MedTech workflows that not only helped sales identify the providers that could benefit from TULSA-PRO but also incorporated reliable commercial intelligence to guide strategic decision-making. Profound Medical also wanted industry-specific functionality for territory, contract, and long-term customer engagement management. After reviewing AcuityMD's platform – including all modules Pipeline, Targeting, Markets, Territories, plus newer modules Contracts and Care Journeys, both launched in 2024 – and speaking to customer referrals, Profound Medical doubled-down on AcuityMD's entire suite. 'We are building something important and want to do it right alongside a technology provider that will partner with us as we grow,' said Tom Tamberrino, Chief Commercial Officer at Profound Medical. 'The people at AcuityMD are as driven to get TULSA-PRO into the market as we are, and their platform is proving instrumental to helping us identify which physicians are treating prostate disease and where, as well as uncovering the high-volume regions where we need to strategically hire more sales professionals.' Tamberrino added, 'We wanted a solution that was more than a one-note sales tool or generic CRM. AcuityMD provides value not just for our sales professionals but also our regional leaders, financial team, marketers, and even manufacturing groups. It's a comprehensive platform solution that delivers industry intelligence that all our teams can use for better decision-making.' AcuityMD's platform is built for the MedTech industry's unique commercialization process and combines streamlined workflows with robust data, enabling sales, marketing, and national accounts teams to build comprehensive strategies focused on their best opportunities. 'Profound Medical is solving a longstanding men's health problem by offering an innovative procedure for prostate disease that also preserves quality-of-life,' said Michael Monovoukas, CEO and co-founder of AcuityMD. 'We are proud to partner with Profound Medical to help identify their best opportunities so they can achieve their goals and bring revolutionary TULSA-PRO technology to as many patients as possible.' AcuityMD is the intelligence platform for MedTech. More than 300 MedTech companies – including six of the top 10 – use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights so companies can understand where and how to sell faster to accelerate the adoption of medical technology. SOURCE: AcuityMD Copyright Business Wire 2025. PUB: 02/26/2025 07:05 AM/DISC: 02/26/2025 07:06 AM
